Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
Dow
McKesson
McKinsey

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

HYDROXYCHLOROQUINE SULFATE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Hydroxychloroquine Sulfate patents expire, and when can generic versions of Hydroxychloroquine Sulfate launch?

Hydroxychloroquine Sulfate is a drug marketed by Accord Hlthcare, Alkaloida Zrt, Amneal Pharms Co, Dr Reddys, Hikma Pharms, Invatech, Ipca Labs Ltd, Lupin Ltd, Mylan, Rising, Sandoz, Senores Pharms, Teva Pharms, Watson Labs, and Zydus Pharms Usa Inc. and is included in fifteen NDAs.

The generic ingredient in HYDROXYCHLOROQUINE SULFATE is hydroxychloroquine sulfate. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the hydroxychloroquine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hydroxychloroquine Sulfate

A generic version of HYDROXYCHLOROQUINE SULFATE was approved as hydroxychloroquine sulfate by TEVA PHARMS on September 30th, 1994.

  Free Forever Trial

Drug patent expirations by year for HYDROXYCHLOROQUINE SULFATE
Drug Sales Revenue Trends for HYDROXYCHLOROQUINE SULFATE

See drug sales revenues for HYDROXYCHLOROQUINE SULFATE

Recent Clinical Trials for HYDROXYCHLOROQUINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
West Virginia UniversityPhase 1/Phase 2
PfizerPhase 2
Abramson Cancer Center of the University of PennsylvaniaPhase 2

See all HYDROXYCHLOROQUINE SULFATE clinical trials

Pharmacology for HYDROXYCHLOROQUINE SULFATE
Medical Subject Heading (MeSH) Categories for HYDROXYCHLOROQUINE SULFATE

US Patents and Regulatory Information for HYDROXYCHLOROQUINE SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare HYDROXYCHLOROQUINE SULFATE hydroxychloroquine sulfate TABLET;ORAL 213342-002 Aug 18, 2021 RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Zydus Pharms Usa Inc HYDROXYCHLOROQUINE SULFATE hydroxychloroquine sulfate TABLET;ORAL 040657-001 Sep 21, 2007 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Dr Reddys HYDROXYCHLOROQUINE SULFATE hydroxychloroquine sulfate TABLET;ORAL 210441-001 May 1, 2018 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Accord Hlthcare HYDROXYCHLOROQUINE SULFATE hydroxychloroquine sulfate TABLET;ORAL 213342-004 Aug 18, 2021 RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Colorcon
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.